Oseltamivir for coronavirus illness: post-hoc exploratory analysis of an open-label, pragmatic, randomised controlled trial in European primary care from 2016 to 2018

Review of the use of oseltamivir for coronaviruses (not including SARS-CoV-2) during three influenza seasons found that the median time to recovery was marginally shorter with oseltamivir plus usual care vs usual care alone (4 vs 5 days, HR 1.31, 95%CI 1.03-1.66)


British Journal of General Practice